Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft Versus Host Disease

The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models

Abstract

Fludarabine phosphate, a purine analogue currently used in the therapy of hematological malignancies, is known to cause immunosuppression and long-lasting T cell lymphopenia. In this study, the effect of fludarabine on murine graft-versus-host disease occurring after marrow transplantation across major and minor histocompatibility barriers was evaluated. Survival of (BALB/c × C57BL/6)F1 mice irradiated and transplanted across the major histocompatibility barrier with C57BL/6 spleen cells, and subsequently treated with fludarabine was significantly longer than that of the control animals (P < 0.0001). On the other hand, fludarabine had no effect on the graft-versus-host disease and survival of cba mice transplanted by b10.br and of BALB/c mice transplanted by b10.d2 spleen cells across the minor histocompatability barrier. The results indicate that in certain murine models, particularly a major mismatch, fludarabine has the potential to induce bilateral tolerance and stable chimerism after marrow transplantation. Bone Marrow Transplantation (2000) 25, 263–266.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation New Engl J Med 1975 292: 832–843

    Article  CAS  PubMed  Google Scholar 

  2. Nash RA, Storb R . Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL Curr Opin Immunol 1996 8: 674–680

    Article  CAS  PubMed  Google Scholar 

  3. Ferrara JLM . Cytokine dysregulation as a mechanism of graft-versus-host disease Curr Opin Immunol 1993 5: 794–799

    Article  CAS  PubMed  Google Scholar 

  4. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 1990 75: 555–562

    CAS  PubMed  Google Scholar 

  5. Slavin S, Ackerstein A, Naparstek E et al . The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 1990 6: 155–161

    CAS  PubMed  Google Scholar 

  6. Truitt RL, Atasoylu AA . Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of NHC-compatible bonemarrow Bone Marrow Transplant 1991 8: 51–58

    CAS  PubMed  Google Scholar 

  7. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts New Engl J Med 1979 300: 1068–1073

    Article  CAS  PubMed  Google Scholar 

  8. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms New Engl J Med 1989 320: 828–834

    Article  CAS  PubMed  Google Scholar 

  9. Pigaditou A, Rohatiner AZS, Whelan JS et al. Fludarabine in low-grade lymphoma Semin Oncol 1993 20: (Suppl. 7) 24–27

    CAS  PubMed  Google Scholar 

  10. Johnson S, Smith AG, Loffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocyte leukaemia. The French Cooperative Group on CLL Lancet 1996 347: 1432–1438

    Article  CAS  PubMed  Google Scholar 

  11. O'Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment Blood 1993 82: 1695–1700

    CAS  PubMed  Google Scholar 

  12. Gandhi V, Estey E, Kentin MJ, Plunkett W . Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 1993 11: 116–124

    Article  CAS  PubMed  Google Scholar 

  13. Wijermans PW, Gerrits WB, Haak HL . Severe immunodeficiency in patients treated with fludarabine monophosphate Eur J Haematol 1993 50: 292–296

    Article  CAS  PubMed  Google Scholar 

  14. Dighiero G . Potential immunological action of purine nucleoside analogues Drugs 1994 47: (Suppl. 6) 57–62

    Article  CAS  PubMed  Google Scholar 

  15. Gratwohl A, Hermans J, Apperley J et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia Blood 1995 86: 813–818

    CAS  PubMed  Google Scholar 

  16. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease New Engl J Med 1993 329: 1225–1230

    Article  CAS  PubMed  Google Scholar 

  17. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study Blood 1995 85: 3746–3753

    CAS  PubMed  Google Scholar 

  18. Goodman ER, Fiedor PS, Fein S et al. Fludarabine phosphate: a DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity Am Surg 1996 62: 435–442

    CAS  PubMed  Google Scholar 

  19. Weiss L, Reich S, Slavin S . Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatability barriers in mice following allogeneic bone marrow transplantation Bone Marrow Transplant 1990 6: 229–233

    CAS  PubMed  Google Scholar 

  20. Chun HG, Leyland-Jones B, Cheson BD . Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies J Clin Oncol 1991 9: 175–188

    Article  CAS  PubMed  Google Scholar 

  21. Mehta J, Powles R, Singhal S et al. T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure Bone Marrow Transplant 1996 17: 881–883

    CAS  PubMed  Google Scholar 

  22. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

  23. Giralt S, Estey E, Albitar N et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536

    CAS  PubMed  Google Scholar 

  24. Kapelushnik J, Or R, Slavin S, Nagler A . A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia Bone Marrow Transplant 1997 20: 1109–1110

    Article  CAS  PubMed  Google Scholar 

  25. Priebe T, Platsoucas CD, Seki H et al. Purine nucleoside modulation of functions of human lymphocytes Cell Immunol 1990 129: 321–328

    Article  CAS  PubMed  Google Scholar 

  26. Myint H, Coppelstone JA, Orchard J et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia Br J Haematol 1995 91: 341–344

    Article  CAS  PubMed  Google Scholar 

  27. Briz M, Cabrera R, Sanjuán I et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia Br J Haematol 1995 91: 409–411

    Article  CAS  PubMed  Google Scholar 

  28. Zulian GB, Roux E, Tiercy JM et al. Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis Br J Haematol 1995 89: 83–89

    Article  CAS  PubMed  Google Scholar 

  29. Briones J, Pereira A, Alcorta I . Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component? Br J Haematol 1996 93: 737–741

    Google Scholar 

  30. Lee TH, Donegan E, Slichter S, Busch MP . Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation Blood 1995 85: 1207–1214

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by an educational grant from Schering, Berlin, Germany.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Or, R., Weiss, L., Amir, G. et al. The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models. Bone Marrow Transplant 25, 263–266 (2000). https://doi.org/10.1038/sj.bmt.1702107

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702107

Keywords

This article is cited by

Search

Quick links